Literature DB >> 11297248

Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder.

T Shirahama1, C Sakakura.   

Abstract

Epidemiological studies indicate that the development of squamous cell carcinoma of the urinary bladder is closely associated with chronic inflammation of the urinary tract, but the underlying mechanism is unknown. Cyclooxygenase (COX)-2 is involved in tumorigenesis in many tumors. The purpose of this study was to investigate the role of COX-2 in squamous cell carcinoma of the urinary bladder by immunoblot and immunohistochemical analyses. COX-2 protein was undetectable in normal bladder samples, but was expressed in 29 of 29 (100%) squamous cell carcinomas and in 8 of 8 (100%) squamous metaplasias. The expression of COX-2 showed intense, homogenous cytoplasmic immunostaining in squamous cell carcinomas. In contrast, COX-2 was heterogeneously expressed in 6 of 12 (50%) cases of transitional cell carcinoma of the bladder combined with squamous cell carcinoma, consistent with previous findings. We provide the first evidence that COX-2 is expressed in squamous cell carcinomas of the urinary bladder and in the precursor lesions, indicating its involvement in the development of this type of malignancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297248

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  Aspirin and urologic cancer risk: an update.

Authors:  Cristina Bosetti; Valentina Rosato; Silvano Gallus; Carlo La Vecchia
Journal:  Nat Rev Urol       Date:  2012-01-24       Impact factor: 14.432

2.  Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.

Authors:  Hong-Xia Li; Xin-Ming Chang; Zheng-Jun Song; Shui-Xiang He
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

3.  Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability.

Authors:  Georgina L Dobek; Xiujuan Zhang; Daniel A Balazs; W T Godbey
Journal:  FASEB J       Date:  2011-05-20       Impact factor: 5.191

Review 4.  Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis.

Authors:  Sarah E Daugherty; Ruth M Pfeiffer; Alice J Sigurdson; Richard B Hayes; Michael Leitzmann; Arthur Schatzkin; Albert R Hollenbeck; Debra T Silverman
Journal:  Am J Epidemiol       Date:  2011-03-02       Impact factor: 4.897

5.  Risk factors for development of primary bladder squamous cell carcinoma.

Authors:  K V Manley; R Hubbard; D Swallow; W Finch; S J Wood; S M Biers
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

6.  Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo.

Authors:  Maria Cekanova; Md Jashim Uddin; Joseph W Bartges; Amanda Callens; Alfred M Legendre; Kusum Rathore; Laura Wright; Amanda Carter; Lawrence J Marnett
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26

7.  PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.

Authors:  Mallika Ghosh; Youxi Ai; Kirsi Narko; Zhenglong Wang; Jeffrey M Peters; Timothy Hla
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-12-24       Impact factor: 3.072

8.  Intermittent self-catheterization and the risk of squamous cell cancer of the bladder: An emerging clinical entity?

Authors:  Rowan G Casey; Ivor M Cullen; Tom Crotty; David M Quinlan
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

9.  Comparison of caspase genes for the induction of apoptosis following gene delivery.

Authors:  Xiujuan Zhang; Curlicia Turner; W T Godbey
Journal:  Mol Biotechnol       Date:  2008-12-09       Impact factor: 2.695

10.  Immunohistochemical expression of COX2 and iNOS in bladder cancer and its association with urinary schistosomiasis among Sudanese patients.

Authors:  Hassan Elsiddig Hassan; Ahmed Abdel Badie Mohamed; Amel Omer Bakhiet; Hussain Gadelkarim Ahmed
Journal:  Infect Agent Cancer       Date:  2013-02-15       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.